1. Home
  2. ELDN vs LPA Comparison

ELDN vs LPA Comparison

Compare ELDN & LPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELDN
  • LPA
  • Stock Information
  • Founded
  • ELDN 2004
  • LPA 2013
  • Country
  • ELDN United States
  • LPA United States
  • Employees
  • ELDN N/A
  • LPA N/A
  • Industry
  • ELDN Biotechnology: Pharmaceutical Preparations
  • LPA
  • Sector
  • ELDN Health Care
  • LPA
  • Exchange
  • ELDN Nasdaq
  • LPA Nasdaq
  • Market Cap
  • ELDN 288.5M
  • LPA 241.7M
  • IPO Year
  • ELDN N/A
  • LPA N/A
  • Fundamental
  • Price
  • ELDN $4.09
  • LPA $10.02
  • Analyst Decision
  • ELDN Strong Buy
  • LPA
  • Analyst Count
  • ELDN 1
  • LPA 0
  • Target Price
  • ELDN $16.00
  • LPA N/A
  • AVG Volume (30 Days)
  • ELDN 520.7K
  • LPA 24.9K
  • Earning Date
  • ELDN 11-12-2024
  • LPA 02-14-2025
  • Dividend Yield
  • ELDN N/A
  • LPA N/A
  • EPS Growth
  • ELDN N/A
  • LPA N/A
  • EPS
  • ELDN N/A
  • LPA N/A
  • Revenue
  • ELDN N/A
  • LPA $44,311,428.00
  • Revenue This Year
  • ELDN N/A
  • LPA N/A
  • Revenue Next Year
  • ELDN N/A
  • LPA N/A
  • P/E Ratio
  • ELDN N/A
  • LPA N/A
  • Revenue Growth
  • ELDN N/A
  • LPA 22.46
  • 52 Week Low
  • ELDN $1.52
  • LPA $6.00
  • 52 Week High
  • ELDN $5.54
  • LPA $525.00
  • Technical
  • Relative Strength Index (RSI)
  • ELDN 47.03
  • LPA N/A
  • Support Level
  • ELDN $3.68
  • LPA N/A
  • Resistance Level
  • ELDN $4.19
  • LPA N/A
  • Average True Range (ATR)
  • ELDN 0.32
  • LPA 0.00
  • MACD
  • ELDN -0.04
  • LPA 0.00
  • Stochastic Oscillator
  • ELDN 31.54
  • LPA 0.00

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.

Share on Social Networks: